Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia.
Balsat M, Alcazer V, Etienne G, Huguet F, Berger M, Cayssials E, Charbonnier A, Escoffre-Barbe M, Johnson-Ansah H, Legros L, Roy L, Delmer A, Ianotto JC, Orvain C, Larosa F, Meunier M, Amé S, Andreoli A, Cony-Makhoul P, Morisset S, Tigaud I, Rea D, Nicolini FE. Balsat M, et al. Among authors: alcazer v. Leuk Res. 2023 Jul;130:107308. doi: 10.1016/j.leukres.2023.107308. Epub 2023 May 9. Leuk Res. 2023. PMID: 37230027
Class I/Class II HLA Evolutionary Divergence Ratio Is an Independent Marker Associated With Disease-Free and Overall Survival After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia.
Daull AM, Dubois V, Labussière-Wallet H, Venet F, Barraco F, Ducastelle-Lepretre S, Larcher MV, Balsat M, Gilis L, Fossard G, Ghesquières H, Heiblig M, Ader F, Alcazer V. Daull AM, et al. Among authors: alcazer v. Front Immunol. 2022 Mar 4;13:841470. doi: 10.3389/fimmu.2022.841470. eCollection 2022. Front Immunol. 2022. PMID: 35309346 Free PMC article.
Distinct Immune Reconstitution Profiles Captured by Immune Functional Assays at 6 Months Post Allogeneic Hematopoietic Stem Cell Transplantation.
Mouton W, Conrad A, Alcazer V, Boccard M, Bodinier M, Oriol G, Subtil F, Labussière-Wallet H, Ducastelle-Lepretre S, Barraco F, Balsat M, Fossard G, Brengel-Pesce K, Ader F, Trouillet-Assant S. Mouton W, et al. Among authors: alcazer v. Transplant Cell Ther. 2023 Feb;29(2):94.e1-94.e13. doi: 10.1016/j.jtct.2022.10.025. Epub 2022 Nov 3. Transplant Cell Ther. 2023. PMID: 36336259 Free article.
Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients.
Gobbini E, Toffart AC, Pérol M, Assié JB, Duruisseaux M, Coupez D, Dubos C, Westeel V, Delaunay M, Guisier F, Veillon R, Gounant V, Giroux Leprieur E, Vanel FR, Chaabane N, Dansin E, Babey H, Decroisette C, Barlesi F, Daniel C, Fournel P, Mezquita L, Oulkhouir Y, Canellas A, Duchemann B, Molinier O, Alcazer V, Moro-Sibilot D, Levra MG. Gobbini E, et al. Among authors: alcazer v. Clin Lung Cancer. 2020 Sep;21(5):e497-e510. doi: 10.1016/j.cllc.2020.04.013. Epub 2020 May 8. Clin Lung Cancer. 2020. PMID: 32605892
Role of Hyperthermic Intraperitoneal Chemotherapy Combined with Cytoreductive Surgery as Consolidation Therapy for Advanced Epithelial Ovarian Cancer.
Frankinet L, Bhatt A, Alcazer V, Classe JM, Bereder JM, Meeus P, Pomel C, Mithieux F, Abboud K, Wermert R, Lavoue V, Marchal F, Glehen O, Bakrin N. Frankinet L, et al. Among authors: alcazer v. Ann Surg Oncol. 2023 Jun;30(6):3287-3299. doi: 10.1245/s10434-023-13242-8. Epub 2023 Feb 23. Ann Surg Oncol. 2023. PMID: 36820940
Cancer vaccines: what's next?
Depil S, Bonaventura P, Alcazer V. Depil S, et al. Among authors: alcazer v. Oncotarget. 2019 Jun 18;10(40):3985-3987. doi: 10.18632/oncotarget.27006. eCollection 2019 Jun 18. Oncotarget. 2019. PMID: 31258838 Free PMC article. No abstract available.
37 results